Health Blueprint

Back to Longevity News

News summary

Vasa Therapeutics Announces Positive Topline Results from Randomized, Placebo-Controlled Phase 1c Trial of VS-041 for Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Source: PR Newswire • Published: 12 Nov 2026, 13:00

Summarized by Masters of Longevity from PR Newswire.

Oral VS-041 lowered NT-proBNP and was well tolerated after 28 days.

Vasa Therapeutics Announces Positive Topline Results from Randomized, Placebo-Controlled Phase 1c Trial of VS-041 for Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)
Key Takeaways
  • VS-041 lowered NT-proBNP within 28 days in HFpEF patients.
  • VS-041 was safe and well tolerated at tested doses.
  • Serum endotrophin was able to identify an HFpEF endotype.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.MoL PickCan Exergaming Improve Balance? What Older Adults Should KnowMotion-controlled games may make balance practice easier to repeat. The evidence supports a structured adjunct—not a fall-proofing shortcut.MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.